YUQORI YOG‘LI RATSION VA SEFTRIAKSON QO‘LLANILGANDA LIPID SPEKTRI HAMDA UGLEVOD ALMASHINUVI KO‘RSATKICHLARINING O‘ZGARISHI VA JIGARNING LIPID TRANSPORT FUNKSIYASI BUZILISHI
Ключевые слова:
yog‘li gepatoz, lipid almashinuvi, triglitseridlar, xolesterin, lipoproteidlarАннотация
Mazkur eksperimental tadqiqotda yuqori yog‘li ratsion va seftriaksonning lipid hamda uglevod almashinuviga alohida va birgalikdagi ta’siri 160 ta oq zotsiz erkak kalamushda o‘rganildi. Tajriba hayvonlari to‘rtta guruhga ajratilib, qon zardobining lipid spektri, glyukoza konsentratsiyasi hamda aterogenlik ko‘rsatkichlari baholandi. Olingan natijalarga ko‘ra, triglitseridlar miqdori yuqori yog‘li ratsion va seftriakson birgalikda qo‘llanilgan guruhda nazorat guruhiga nisbatan 7,25 barobar, faqat yuqori yog‘li ratsion ta’sirida esa 6,33 barobar oshdi. Faqat seftriakson qo‘llanilgan guruhda umumiy xolesterin miqdori 75,8% ga, past zichlikdagi lipoproteidlar xolesterini esa 4,4 barobar oshgani aniqlandi. Birgalikdagi ta’sir sharoitida xolesterin ko‘rsatkichlarining oshishi nisbatan cheklangan bo‘lib, juda past zichlikdagi lipoproteidlar xolesterini barcha tajriba guruhlarida kamayganligi kuzatildi. Tadqiqot natijalari yuqori yog‘li ratsion va seftriaksonning lipid almashinuviga turlicha ta’sir ko‘rsatishini hamda jigarning lipid transport funksiyasi buzilishi ehtimolini ko‘rsatadi. Aniqlangan metabolik o‘zgarishlar dislipidemiya rivojlanish mexanizmlarini o‘rganishda lipid spektri ko‘rsatkichlarini kompleks baholash zarurligini asoslaydi.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Rinella M.E., Lazarus J.V., Ratziu V. va boshqalar. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 2023, 79(6), 1542–1556. https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext
2. Schoeler M., Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Reviews in Endocrine and Metabolic Disorders, 2019, 20(4). https://pmc.ncbi.nlm.nih.gov/articles/PMC6938793/
3. Sun L., Xie C., Wang G. va boshqalar. The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. Journal of Clinical Medicine, 2019, 8(12), 2227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947520/
4. Cui X., Yuan Q., Long J., Zhou J. Recent advances in gut microbiota-mediated regulation of fat deposition and metabolic disorders. Microbiome Research Reports, 2025. https://doi.org/10.20517/mrr.2025.25
5. Sarkar A., Ghosh S. va boshqalar. Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer? Disease Markers, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847007/
6. Chambers E.S., Preston T., Frost G., Morrison D.J. Gut microbial metabolite short-chain fatty acids and obesity. Current Nutrition Reports, 2018, 7(4). https://pmc.ncbi.nlm.nih.gov/articles/PMC5633527/
7. Chen T.C., Yen C.H. va boshqalar. Lactobacillus rhamnosus Ameliorates Dyslipidemia and Liver Steatosis in a Rat Model Fed High-Fat Diet. Nutrients, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12537184/
8. Stankiewicz-Drogon A., Skrzypczak-Zielinska M., Dobrowolska A. va boshqalar. Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease with Lipopolysaccharides Secretion. Diagnostics, 2019, 9(4), 205. https://www.mdpi.com/2075-4418/9/4/205
9. Gao H., Shu Q., Chen J. va boshqalar. Antibiotic Exposure Has Sex-Dependent Effects on the Gut Microbiota and Metabolism of Short-Chain Fatty Acids and Amino Acids in Mice. mSystems, 2019, 4(4). https://doi.org/10.1128/mSystems.00048-19
10. Xia J., Jin Y., Hong Y. va boshqalar. Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats: from endogenous to ceftriaxone-induced dysbiosis. Frontiers in Microbiology, 2025. https://doi.org/10.3389/fmicb.2025.1693247
11. Pezzino S., Sofia M., Faletra G. va boshqalar. Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. Biology, 2022, 11(11), 1622. https://doi.org/10.3390/biology11111622
12. Ma Z., Zhang Y., Li Q. va boshqalar. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Scientific Reports, 2017, 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353673/
13. Ferro D., Baratta F., Pastori D. va boshqalar. Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance. Frontiers in Microbiology, 2025. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1645298/full
14. Rau M., Geier A. va boshqalar. Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease. Livers, 2024, 4(3), 32. https://www.mdpi.com/2673-4389/4/3/32
15. Ferolla S.M., Armiliato G.N., Couto C.A., Ferrari T.C. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? Nutrients, 2023, 15(6). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052062/
16. Oliphant K., Allen-Vercoe E. va boshqalar. Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles. Gut Microbes, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6451719/
17. Sharma A., Mehta V. va boshqalar. Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease. Cureus, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828853/
18. Polyzos S.A., Kountouras J. va boshqalar. Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease. Endocrine, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291610/
19. Song Q., Zhang X. va boshqalar. Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a cross-study re-analysis. Frontiers in Cellular and Infection Microbiology, 2026. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1822390/full
20. Kolaric T.O., Nincevic V., Kuna L. va boshqalar. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options. Nutrients, 2024, 16(14). https://pubmed.ncbi.nlm.nih.gov/39057689/
